Medtronic, drug coated balloon, peripheral artery disease

Medtronic Takes Manufacturing to Galway

By MedTech Intelligence Staff
Medtronic, drug coated balloon, peripheral artery disease

The company will invest €13 million in the facility, which will make drug-coated balloons for peripheral artery disease.

Medtronic is investing €13 million in a high-tech 20,000 square foot facility in Galway, Ireland that will be the manufacturing site for the company’s drug-coated balloon. About 8000 square feet of space will be dedicated to the manufacturing of the IN.PACT Admiral device, which is used for the treatment of peripheral artery disease.

Ireland Remains Competitive in Medical Device Sector“Our global market leadership in DCB [drug-coated balloons] is driving the need to open the new facility here in Galway to provide more patients access to this highly efficacious and safe treatment option for peripheral arterial disease,” said Tony Semedo, senior vice president and president of the Aortic & Peripheral Vascular business at Medtronic in a company release. “Our Galway operations and staff have very specific expertise in this area, which is the platform for this announcement.  Once fully operational, this facility will be the only DCB manufacturing area of its kind in Medtronic worldwide.”

The company selected Galway due to its on-site expertise in combination products for its coronary business. The facility will be home to about 100 employees who have backgrounds in quality and manufacturing engineering, and supply chain and production management.

Related Articles

  • Axendia 2023 Events Logo

    Share your research, experience and expertise with your peers at the upcoming Medtech Advanced Manufacturing Conference and Medtech Supply Chain Intelligence Summit. Call for abstracts is now open.

  • FFRangio System

    Medtronic will invest up to $75 million and immediately begin co-promotion of CathWorks’ FFRangio System for the noninvasive diagnosis of CAD in the U.S., Europe and Japan, where it is commercially available.

  • Emily Newton, Revolutionized Magazine

    Excess humidity can affect a pharmaceutical’s structure, chemical stability and dissolving rate, and this moisture can come in contact with product at multiple points throughout production and shipping. Fortunately, new technologies are making it easier for manufacturers and shippers to…

  • Critical Manufacturing and Dataworks

    “Many medical device and life sciences companies are still carrying out manual validation processes, using paper-based scripts, screen shots and pdfs. However, regulatory bodies, such as the FDA, are encouraging companies to take a more automated approach using computer system…

About The Author

MedTech Intelligence